EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Current use of percutaneous ablation in renal tumors: an analysis of the registry of the German Society for Interventional Radiology and Minimally Invasive Therapy

Benedikt M Schaarschmidt, Sebastian Zensen, Claudia Kesch, Thomas Dertnig, Marcel Opitz, Marcel Drews, Jonathan Nadjiri, Michael Forsting, Boris A Hadaschik, Johannes Haubold

European Radiology · 2025

DOI: 10.1007/s00330-024-11343-w ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Radiology, 2025. Verfasst von Benedikt M Schaarschmidt und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany. benedikt.schaarschmidt@uk-essen.d…. Hauptthemen laut MEDLINE: Catheter Ablation, Kidney Neoplasms, Registries. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the success and complications of thermal ablation (TA) based on the voluntary, prospective registry of the German Society for Interventional Radiology and Minimally Invasive Therapy (DeGIR) with 303 participating centers from Germany, Austria, and Switzerland. Materials and methods Registry data from 2018 until 2023 of 1102 patients with small renal tumors (age: 72.5 ± 11.6 years; female: 33.6%, 370/1102) were analyzed. Hospitals with ≥ 20 TAs were considered high-volume centers. Technical success and complication rates between different parameters were compared using the chi-square or Fisher’s exact test, p < 0.05 was considered statistically significant.

Results

Patients were most frequently treated with radiofrequency ablation (RFA, 43.6%, 481/1102), then microwave ablation (MWA, 41.9%, 462/1102) or cryoablation (13.3%, 147/1102). Technical success for heat-based TA (RFA&MWA) was 94.3% (893/947), for cryoablation 97.3% (143/147). RFA&MWA was significantly more successful in lesions ≤ 3 cm (96.1%, 567/590) compared to 3–4 cm lesions (89.8%, 97/108; p = 0.005). In patients treated with cryoablation, no significant differences between sizes could be found (≤ 3 cm: 97.9%, 94/96; 3–4 cm: 85.7%, 12/14; p = 0.078). Complication rate was significantly higher in RFA&MWA of lesions 3–4 cm compared to ≤ 3 cm (≤ 3 cm: 3.9%, 23/590; 3–4 cm: 11.1%, 12/108, p = 0.002), while no significant differences were seen regarding cryoablation (≤ 3 cm: 1.0%, 1/96; 3–4 cm: 0.0%, 0/14; p = 1.000).

Conclusions

In this exploratory analysis of the DeGIR registry, percutaneous TA of small renal masses is technically feasible with low complication rates. Heat-based TAs seem to have lower success rates and higher complication rates in larger tumors. Cryoablation could potentially be a safe alternative for 3- to 4-cm-sized tumors. Key Points Question How effective is renal thermal ablation (TA) in terms of treatment success and complication rates?

Findings

In contrast to cryoablation, heat-based thermal ablation has lower success and higher complication rates in tumors measuring 3–4 cm compared to tumors < 3 cm . Clinical relevance Thermal ablation is not influenced by the need for additional techniques such as cooling, protective organ displacement, or temporary vessel occlusion. For small renal tumors, TA is an effective and safe treatment option. Cryoablation could be beneficial in larger tumors. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Catheter AblationKidney NeoplasmsRegistriesAgedAged, 80 and overFemaleHumansMaleMiddle AgedAustriaCryosurgeryGermanyMinimally Invasive Surgical ProceduresProspective StudiesRadiofrequency AblationRadiology, InterventionalSocieties, MedicalSwitzerlandTreatment Outcome

Stichwörter der Autor:innen

CryoablationKidneyMicrowave ablationRadiofrequency ablation

Autor:innen und Institutionen

  • Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany. benedikt.schaarschmidt@uk-essen.de.
  • Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
  • Department of Urology, University Hospital Essen, Essen, Germany.
  • Department of Interventional Radiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.

Zitieren

APA

Schaarschmidt, B. M., Zensen, S., Kesch, C., Dertnig, T., Opitz, M., Drews, M., Nadjiri, J., Forsting, M., Hadaschik, B. A., & Haubold, J. (2025). Current use of percutaneous ablation in renal tumors: an analysis of the registry of the German Society for Interventional Radiology and Minimally Invasive Therapy. European Radiology. https://doi.org/10.1007/s00330-024-11343-w

Vancouver

Schaarschmidt BM, Zensen S, Kesch C, Dertnig T, Opitz M, Drews M, et al. Current use of percutaneous ablation in renal tumors: an analysis of the registry of the German Society for Interventional Radiology and Minimally Invasive Therapy. European Radiology. 2025. doi:10.1007/s00330-024-11343-w

BibTeX
@article{Schaarschmidt2025,
  author = {Schaarschmidt, Benedikt M and Zensen, Sebastian and Kesch, Claudia and Dertnig, Thomas and Opitz, Marcel and Drews, Marcel and Nadjiri, Jonathan and Forsting, Michael and Hadaschik, Boris A and Haubold, Johannes},
  title = {Current use of percutaneous ablation in renal tumors: an analysis of the registry of the German Society for Interventional Radiology and Minimally Invasive Therapy},
  journal = {European Radiology},
  year = {2025},
  doi = {10.1007/s00330-024-11343-w}
}
Kostenlos starten →